Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
2.750
-0.030 (-1.08%)
Dec 20, 2024, 4:00 PM EST - Market closed
Puma Biotechnology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 243.57 | 235.64 | 228.03 | 253.16 | 225.11 | 272.26 | Upgrade
|
| Revenue Growth (YoY) | 6.30% | 3.34% | -9.92% | 12.46% | -17.32% | 8.47% | Upgrade
|
| Cost of Revenue | 74.81 | 62.68 | 55.09 | 63.7 | 39.37 | 36.82 | Upgrade
|
| Gross Profit | 168.76 | 172.96 | 172.94 | 189.45 | 185.74 | 235.45 | Upgrade
|
| Selling, General & Admin | 83.1 | 89.31 | 91.98 | 116.29 | 118.49 | 140.46 | Upgrade
|
| Research & Development | 52.64 | 50.38 | 52.24 | 71.87 | 97.65 | 132.85 | Upgrade
|
| Operating Expenses | 135.74 | 139.69 | 144.22 | 188.16 | 216.14 | 273.31 | Upgrade
|
| Operating Income | 33.02 | 33.27 | 28.72 | 1.29 | -30.4 | -37.86 | Upgrade
|
| Interest Expense | -13.19 | -13.33 | -11.59 | -12.81 | -14.05 | -15.02 | Upgrade
|
| Interest & Investment Income | 4.22 | 2.61 | 0.81 | 0.16 | 0.49 | 2.85 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.4 | 0.4 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.84 | 0.36 | -0.03 | 0.29 | 0.37 | 0.13 | Upgrade
|
| EBT Excluding Unusual Items | 25.29 | 23.3 | 17.91 | -11.07 | -43.59 | -49.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 | Upgrade
|
| Asset Writedown | -0.63 | -0.63 | - | - | - | -1.18 | Upgrade
|
| Legal Settlements | - | - | -12.46 | -9.59 | -16.2 | -16.35 | Upgrade
|
| Other Unusual Items | - | - | 2 | -8.15 | - | -8.1 | Upgrade
|
| Pretax Income | 24.67 | 22.67 | 0.46 | -28.8 | -59.79 | -75.54 | Upgrade
|
| Income Tax Expense | 1.43 | 1.08 | 0.46 | 0.32 | 0.21 | 0.05 | Upgrade
|
| Net Income | 23.24 | 21.59 | 0 | -29.13 | -60 | -75.6 | Upgrade
|
| Net Income to Common | 23.24 | 21.59 | 0 | -29.13 | -60 | -75.6 | Upgrade
|
| Net Income Growth | 525.26% | 1079450.00% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 48 | 47 | 45 | 41 | 40 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 48 | 45 | 41 | 40 | 39 | Upgrade
|
| Shares Change (YoY) | 3.48% | 5.83% | 10.56% | 2.69% | 2.08% | 2.18% | Upgrade
|
| EPS (Basic) | 0.48 | 0.46 | 0.00 | -0.72 | -1.52 | -1.95 | Upgrade
|
| EPS (Diluted) | 0.47 | 0.45 | 0.00 | -0.72 | -1.52 | -1.95 | Upgrade
|
| EPS Growth | 492.79% | 1022625.00% | - | - | - | - | Upgrade
|
| Free Cash Flow | 33.68 | 26.87 | -22.83 | 20.65 | 0.73 | 22.07 | Upgrade
|
| Free Cash Flow Per Share | 0.69 | 0.57 | -0.51 | 0.51 | 0.02 | 0.57 | Upgrade
|
| Gross Margin | 69.29% | 73.40% | 75.84% | 74.84% | 82.51% | 86.48% | Upgrade
|
| Operating Margin | 13.56% | 14.12% | 12.59% | 0.51% | -13.51% | -13.91% | Upgrade
|
| Profit Margin | 9.54% | 9.16% | 0.00% | -11.51% | -26.65% | -27.77% | Upgrade
|
| Free Cash Flow Margin | 13.83% | 11.40% | -10.01% | 8.16% | 0.32% | 8.11% | Upgrade
|
| EBITDA | 44.6 | 44.78 | 38.56 | 12.6 | -20.37 | -29.79 | Upgrade
|
| EBITDA Margin | 18.31% | 19.01% | 16.91% | 4.98% | -9.05% | -10.94% | Upgrade
|
| D&A For EBITDA | 11.57 | 11.52 | 9.84 | 11.31 | 10.03 | 8.08 | Upgrade
|
| EBIT | 33.02 | 33.27 | 28.72 | 1.29 | -30.4 | -37.86 | Upgrade
|
| EBIT Margin | 13.56% | 14.12% | 12.59% | 0.51% | -13.51% | -13.91% | Upgrade
|
| Effective Tax Rate | 5.78% | 4.78% | 99.56% | - | - | - | Upgrade
|
| Revenue as Reported | 243.57 | 235.64 | 228.03 | 253.16 | 225.11 | 272.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.